多囊卵巢综合征患者血清尾加压素Ⅱ水平测定及其临床意义

Determination of Serum Caudal Vasopressin Ⅱ in Patients With Polycystic Ovary Syndrome and its Clinical Significance

目的检测多囊卵巢综合征(PCOS)患者血清尾加压素Ⅱ(UⅡ)水平并探讨其临床意义。方法采用酶联免疫吸附法(ELISA)检测40例PCOS患者(其中肥胖组25例和非肥胖组15例)及30例正常对照者血清UⅡ水平。通过检测空腹血糖(FBG)、空腹胰岛素(FIN)计算稳态模型胰岛素抵抗指数(HOMA-IR)。结果 PCOS患者血清UⅡ及HOMA-IR均高于对照组,差异具有统计学意义(P<0.05);PCOS患者肥胖组血清UⅡ及HOMA-IR均高于非肥胖组,差异具有统计学意义(P<0.05);UⅡ和HOMA-IR在PCOS中呈正相关性(P<0.05)。结论 UⅡ和胰岛素抵抗(IR)参与了PCOS的发生、发展,且IR更易发生于PCOS肥胖者。

Objective Testing in patients with polycystic ovarian syndrome （PCOS） serum levels of UII and to explore its clinical significance. Methods Detection serum levels of UII by enzyme-linked immunosorbent method （ELISA） in 40 patients with PCOS （including obese group 25 cases and non-obese group 15 cases） and 30 cases of normal controls.Through testing the fasting blood glucose （FBG）, fasting insulin （FIN） computing the steady state model of insulin resistance index （HOMA-IR）. Results The serum UII and HOMA-IR in patients with PCOS were higher than those of control group, the diference was statistically signifcant （P 〈 0.05）; the serum UII and HOMA-IR in patients with obese group were higher than those of non-obese group, the diference was statistically signifcant （P 〈 0.05）; the level of UII had a positive correlation with HOMA-IR （P 〈 0.05）.Conclusion UII and insulin resistance （IR） take part in the occurrence and development of PCOS, and obese PCOS patients may have the risk of IR.